What Biofenac (Aceclofenac) Treats: Main Uses and Benefits

Biofenac (Aceclofenac) is commonly used to help with symptoms related to inflammatory or irritative states, primarily applied across domains where additional symptomatic support is needed. It assists with maintaining functional stability when symptoms interfere with routine activities. Its application is associated with symptomatic relief across several key areas of physical discomfort.

The medication may be part of symptomatic management in conditions involving episodic or fluctuating manifestations, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is commonly used to help with symptoms that become more disruptive during flare-ups, such as the persistent cluster of joint pain, associated swelling, and stiffness. It supports general well-being during symptomatic phases and assists with maintaining functional stability.

Aceclofenac is also applicable within clinical settings that involve acute or disruptive symptom patterns, relevant when supportive symptom management is appropriate. This includes short-term symptomatic assistance for local episodes like lumbago (lower back pain), and specific conditions such as primary dysmenorrhea or acute pain associated with dental conditions. It is relevant for easing symptoms related to inflammatory or irritative states.

Quick Fact: Symptom Relief Focus
Primary Use: Symptomatic management of pain and inflammation in chronic joint diseases (e.g., RA, OA).
Acute Contexts: Applied in scenarios requiring additional management of discomfort from post-trauma or acute episodic changes.
Patient Benefit: Provides support that helps ease the overall symptom burden and supports general well-being.

Who Can and Cannot Use Biofenac (Aceclofenac)?

The eligibility profile for Aceclofenac is strictly defined by government regulatory documents, focusing on patient characteristics and pre-existing conditions.

---

Contraindicated Populations (Absolute Non-Eligibility)

Population/Condition	Restriction Basis
Hypersensitivity	To Aceclofenac, any excipient, or previous NSAIDs/aspirin (e.g., precipitated asthma).
Cardiovascular Disease	Established Congestive Heart Failure (NYHA II–IV), Ischaemic Heart Disease, Peripheral Arterial Disease, and/or Cerebrovascular Disease.
Organ Failure	Severe Hepatic Failure or Severe Renal Failure.
Gastrointestinal Disease	Active or history of recurrent peptic ulcer/haemorrhage, or GI bleeding/perforation related to previous NSAID therapy.
Pregnancy	Use during the Third Trimester of pregnancy.

---

Age-Related and Conditional Eligibility

Age Group/Condition	Regulatory Status
Pediatric Population	Not recommended for use in children and adolescents under 18 years due to insufficient clinical data.
Elderly Population	Use requires special caution due to increased risk of serious adverse reactions, particularly GI bleeding and perforation.
Mild/Moderate Impairment	Patients with mild to moderate Hepatic or Renal impairment require close medical surveillance.
Reproductive Status	Use is not recommended during First and Second Trimester of Pregnancy, during Lactation, or for women actively attempting to conceive.

---

Resulting Eligibility Structure

Official eligibility statements mandate that the medicine is contraindicated based on severe systemic disease, organ failure, or known hypersensitivity to the drug class. The profile permits use primarily in adults but requires caution and monitoring for patients with mild-to-moderate organ impairment, cardiovascular risk factors, or advanced age, and is not recommended for pediatric patients or during specific stages of pregnancy.

Interactions with Other Medicines and Products

The interaction profile of aceclofenac is structured around the potential for synergistic adverse effects, primarily increased risk of bleeding, and pharmacokinetic changes affecting other medications. Official regulatory documents outline specific constraints regarding concomitant use.

---

Documented Interaction Domains and Constraints

Interaction Domain	Practical Implication (Regulatory Constraint)
Other Non-Steroidal Anti-inflammatory Drugs (NSAIDs)	Concomitant use with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided to prevent an increased frequency of adverse reactions.
Anticoagulants (e.g., Warfarin) & Antiplatelet Agents (e.g., Aspirin), Corticosteroids, SSRIs	Caution is mandatory due to a significantly increased risk of gastrointestinal bleeding and ulceration. Protection (e.g., proton pump inhibitors) may be considered for high-risk patients.
Diuretics, ACE Inhibitors, Angiotensin II Receptor Antagonists	Requires caution and monitoring of renal function, as aceclofenac may reduce the antihypertensive and diuretic efficacy and potentially lead to deterioration of renal function, particularly in the elderly.
Lithium & Digoxin	Close monitoring of serum concentrations is necessary due to the potential for aceclofenac to increase the plasma levels and toxicity of these medicines.
Methotrexate, Cyclosporin, Tacrolimus	Combination use requires caution and clinical monitoring, as aceclofenac may increase the concentration or toxicity of these medicines, affecting kidney function.

---

Interaction Classifications: The constraints defined in official labeling range from Avoidance (for NSAID combinations) to Use with Caution and Monitoring Required (for drugs where increased toxicity or reduced efficacy is a risk). Elderly patients, or those with existing cardiovascular or renal risk factors, are identified as populations requiring heightened vigilance regarding these drug interactions.

How Biofenac (Aceclofenac) Works

The action of Biofenac (Aceclofenac) is mechanistic, focusing on the molecular and cellular processes that lead to its physiological effects. The drug functions primarily through two core mechanistic domains that together modulate specific signaling pathways.

---

Key Domain 1: Enzymatic Blockade of Prostaglandin Synthesis

This domain covers the drug's molecular targets and primary interaction. Aceclofenac acts as a competitive inhibitor of the Cyclooxygenase ( COX) enzyme, specifically targeting the inducible COX-2 isoform . By blocking the COX enzyme, the drug interrupts the Eicosanoid Biosynthesis Pathway, reducing the creation of Prostaglandins ( PGs), which are chemical messengers that mediate local responses.

---

Key Domain 2: Modulating Peripheral Nociceptive Signaling

This domain addresses the causal chain from the biochemical change to the physiological effect. The resulting reduction in PGs, particularly PGE2, causes the de-sensitization of peripheral nociceptors (sensory neurons). This mechanism modulates the activity within the sensory system by increasing the threshold required for signal transmission, which in turn results in the modulation of afferent signaling pathways.

Official Administration Guidelines

Biofenac (Aceclofenac) is provided as a 100 mg film-coated tablet intended for oral administration. Guidelines mandate that the medication must be used at the lowest effective dose for the shortest duration necessary to manage symptoms, establishing a core principle for the overall use protocol.

---

The following parameters define the official usage instructions.

Usage Parameter	Official Instruction (Label-Based)
Standard Adult Dose	200 mg total daily dose, taken as two separate 100 mg doses.
Dosing Frequency	Twice daily (BID), typically one dose in the morning and one in the evening.
Timing in Relation to Meals	Tablets should be swallowed whole with or after food.
Preparation/Handling	Tablets must not be chewed or crushed.
Hepatic Adjustment	Initial dose should be reduced to 100 mg daily for patients with mild-to-moderate hepatic impairment.
Older Adults / Pediatrics	No dose modification is necessary for older adults. Use is not recommended in children under 18 years.
Missed Dose Rule	If a dose is missed, do not take a double dose; return to the usual schedule.

---

This instruction set precisely defines the quantity, frequency, administration technique, and required dose modifications, structuring the proper clinical administration of the medicine.

Research Evidence / Overview of Studies for Biofenac (Aceclofenac)

This section provides an overview of the official research studies and clinical trials that have examined Aceclofenac (Biofenac), focusing on what researchers explored and what is known so far, according to authoritative sources. The evidence highlights what is known—and what is still uncertain—about group patterns, and research does not determine whether an individual will respond similarly.

---

Evidence for Use in Chronic Inflammatory Joint Conditions

The research base for Aceclofenac primarily includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews, which are used in research exploring how symptoms change over time in conditions such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), where research examined symptomatic patterns. These studies were applied in studies examining patient-reported experiences related to systemic or functional imbalance.

Research on Osteoarthritis

Research has explored the use of Aceclofenac in adult populations diagnosed with Osteoarthritis (OA), a condition marked by functional limitations and periods of heightened symptoms. The main focus of these intermediate-term studies (lasting several months) was to observe outcomes related to physical discomfort using standardized pain intensity scales. However, evidence remains limited regarding the sustained effects, as long-term outcomes are not fully established, and follow-up durations were limited for some trials.

Research on Rheumatoid Arthritis

Research explored the application of Aceclofenac in Rheumatoid Arthritis (RA). Trials monitored outcomes reflecting systemic imbalance, such as disease activity scores and counts of swollen and tender joints. Findings describe patterns observed in these intermediate-term studies involving adult patients. While research contributes to the broader evidence landscape for symptomatic patterns, data for certain groups remain insufficient.

---

Evidence for Use in Acute and Episodic Pain Conditions

Research for acute pain is relevant in trials assessing short-term or episodic symptom patterns associated with acute or disruptive episodes. This includes conditions such as lumbago (lower back pain), primary dysmenorrhea, and pain associated with dental conditions. These studies, which are very short-term, monitored outcomes describing episodic or acute changes, focusing on factors like the speed of symptomatic change. Studies help show what has been observed so far, confirming that the available evidence primarily describes short-term symptomatic change in acute settings.

---

What is Still Uncertain About Aceclofenac (Biofenac)

Research contributes to the broader evidence landscape, but some key areas remain uncharacterized. The long-term effects are not fully established, as controlled trial evidence often ends at the six-month mark. The evidence quality varies across studies, and sometimes findings were mixed regarding direct comparisons to other similar medicines. Data for certain specific groups, such as those with certain concurrent health issues, remain insufficient.

Common questions about Biofenac (Aceclofenac) (FAQ)

Q: Is Biofenac (Aceclofenac) available over-the-counter or does it need a prescription?

A: According to official regulatory documents, Biofenac (Aceclofenac) is classified as a prescription-only medicine (Rx). This means it requires a prescription from a qualified healthcare professional before it can be dispensed and is not available for purchase over-the-counter.

Q: What are the most common side effects of Biofenac?

A: Official product information, based on clinical reporting, classifies adverse reactions by frequency. The side effects most commonly reported include gastrointestinal issues such as dyspepsia (indigestion), abdominal pain, nausea, and diarrhoea. Other common reported reactions include dizziness and increased hepatic enzymes (changes in liver function tests).

Q: How quickly does Biofenac start working for pain relief?

A: Regulatory studies on the drug's absorption indicate that Aceclofenac is absorbed relatively quickly after the tablet is ingested. Maximum concentration in the bloodstream, known as the peak plasma concentration, is typically reached within approximately one and a quarter to three hours after taking the tablet.

Q: What is the shelf life of Biofenac tablets from the date of manufacture?

A: Regulatory labels for the medicine address the product’s stability, which determines how long it remains effective. The stated shelf life for Biofenac is typically three years from the date of manufacture, contingent on storage according to the official guidelines.

Q: Can I take Biofenac if I'm breastfeeding?

A: Official regulatory information states that the use of this medicine during breastfeeding (lactation) is generally not recommended. There is typically limited or no official information regarding whether or not Aceclofenac is secreted into breast milk, which is a key factor in this recommendation.

Q: Is it safe to drive after taking Biofenac?

A: The regulatory label indicates that caution should be exercised regarding driving or operating machinery. This is because some reported side effects, such as dizziness or visual disturbance, may occur and could affect the ability to perform these tasks.

How to Store and Dispose of Aceclofenac?

---

Storage Guidelines

To ensure the stability and effectiveness of aceclofenac (Biofenac), store the medicine at room temperature, typically between 15 C and 30 C (59 F and 86 F). Keep it in its original container, tightly closed, and protect it from excessive heat and moisture. Do not store aceclofenac in the bathroom or near a kitchen sink. Keep the medication out of the reach of children and pets.

---

Disposal

Dispose of aceclofenac that is expired or no longer needed properly. The safest method is often to take it to a drug take-back program. If a take-back program is unavailable, consult your pharmacist or local waste disposal service for guidance. Do not flush this medication down the toilet or pour it down a drain unless specifically instructed to do so by a healthcare provider or official guidelines, as this can pose environmental risks.